Like cancer, fibrotic diseases are the result of complex biological processes that are similar in their final outcome, but diverse in the molecular mechanisms underlying those processes. Thus, identifying treatment targets and developing effective therapies is extremely difficult. It requires a continuous dialogue between basic scientists, translational researchers and clinical investigators across a range of disciplines.
The Joan & Joel Rosenbloom Center for Fibrotic Diseases, established in 2013, is an interdepartmental research program focusing on diagnosis, disease mechanisms, prevention and treatment of fibrotic diseases. It acts as a bridge: both to translate basic findings into drug therapies and to bring basic and clinical researchers together in novel studies that often cross fields and diseases.
"The Joan & Joel Rosenbloom Center for Fibrotic Diseases,"
Thomas Jefferson University Research Magazine: Vol. 1:
1, Article 31.
Available at: https://jdc.jefferson.edu/researchmagazine/vol1/iss1/31